Diagnosis and treatment of CD20 negative B cell lymphomas

被引：25
|
作者：
Katchi, Tasleem
Liu, Delong [1 ]
机构：
[1] New York Med Coll, Div Hematol & Oncol, Valhalla, NY 10595 USA
来源：
BIOMARKER RESEARCH | 2017年 / 5卷
关键词：
DOSE-ADJUSTED EPOCH; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BRUTON TYROSINE KINASE; CODOX-M/IVAC; BURKITT-LYMPHOMA; PHASE-II; HODGKINS-LYMPHOMA; POOR-PROGNOSIS; FOLLOW-UP;
D O I：
10.1186/s40364-017-0088-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20-negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] The identification of CD20 negative/low memory B cells in pemphigus patients
    Stamey, C.
    Pasieka, H. B.
    Anhalt, G.
    Diaz, L.
    Culton, D. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (08) : S1 - S1
  • [32] CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20(+), surface CD20(-)
    Yokose, Norio
    Shioi, Yumiko
    Sugisaki, Yuich
    Ohaki, Yoshiharu
    Ogata, Kiyoyuki
    Dan, Kazuo
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1415 - 1417
  • [33] CD20 negative primary diffuse large B cell lymphoma of breast: Role of Pax-5
    Shukla, Saumya
    Awasthi, Namrata Punit
    Singh, Pradyumn
    Husain, Nuzhat
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (03) : 658
  • [34] Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia
    Kumar, Jeevan
    Khan, Afaq Ahmad
    Saraf, Amrita
    Bhargava, Manorama
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2014, 30 (01) : 16 - 18
  • [35] Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia
    Jeevan Kumar
    Afaq Ahmad Khan
    Amrita Saraf
    Manorama Bhargava
    Indian Journal of Hematology and Blood Transfusion, 2014, 30 : 16 - 18
  • [36] Quantitative difference in CD20 expression in chronic B-cell lymphocytic leukemia and lymphomas by site and type of disease.
    Huh, YO
    Keating, MJ
    Saffer, H
    Jilani, I
    Albitar, M
    BLOOD, 2000, 96 (11) : 371A - 371A
  • [37] CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
    Shadman, Mazyar
    Gopal, Ajay K.
    Smith, Stephen D.
    Lynch, Ryan C.
    Ujjani, Chaitra S.
    Turtle, Cameron J.
    Greenbaum, Adam
    Redman, Mary
    Yeung, Cecilia
    Sersch, Martina
    Warren, Edus H.
    Maloney, David G.
    Till, Brian G.
    BLOOD, 2019, 134
  • [38] Levels of expression of CD19 and CD20 in chronic B cell leukaemias
    Ginaldi, L
    De Martinis, M
    Matutes, E
    Farahat, N
    Morilla, R
    Catovsky, D
    JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (05) : 364 - 369
  • [39] Anti CD20 Radioimmunotherapy and mTOR Inhibition in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas
    Umyarova, Elvira
    Chhabra, Saurabh
    Mims, Alice
    Stuart, Robert
    Costa, Luciano J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S316 - S317
  • [40] Regulation of CD20 in rituximab-resistant cell lines (RRCL) and B-cell non-Hodgkin's lymphomas (NHL)
    Tsai, Ping-Chiao
    Nayeen, Bangia
    Olejniczak, Scott
    Hernandez-Ilizaliturri, Francisco
    Czuczman, Myron
    JOURNAL OF IMMUNOLOGY, 2010, 184
12345